Low-molecular-weight heparin in radial artery occlusion treatment: the LOW-RAO randomized study.

Future cardiology 2022 Feb

filter terms:

Radial artery occlusion (RAO) is the commonest complication of transradial catheterization. There is no evidence-based therapy, in the frame of a randomized control study, for the treatment of RAO. The purpose of the LOW-RAO study is to question the hypothesis if low-molecular-weight hepa rin is effective in the treatment of RAO after transradial coronary catheterization (both angiography and percutaneous coronary intervention). It is a prospective, open label, randomized controlled trial that will randomize 60 patients with RAO, irrespective of symptoms, into two groups, one receiving anticoagulation with low-molecular-weight hepa rin and the other receiving no treatment. The primary end point is improvement in radial artery patency rate at 4 weeks after the procedure. Clinical trial registration number: NCT04196309 (ClinicalTrials.gov).

Citation

Matthaios Didagelos, Areti Pagiantza, Thomas Zegkos, Christos Papanastasiou, Konstantina Zarra, Vasileios Angelopoulos, Antonios Kouparanis, Emmanouela Peteinidou, George Sianos, Haralambos Karvounis, Antonios Ziakas. Low-molecular-weight heparin in radial artery occlusion treatment: the LOW-RAO randomized study. Future cardiology. 2022 Feb;18(2):91-100